Organon Net Worth
Organon Net Worth Breakdown | OGN |
Organon Net Worth Analysis
Organon's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Organon's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Organon's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Organon's net worth analysis. One common approach is to calculate Organon's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Organon's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Organon's net worth. This approach calculates the present value of Organon's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Organon's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Organon's net worth. This involves comparing Organon's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Organon's net worth relative to its peers.
Enterprise Value |
|
To determine if Organon is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Organon's net worth research are outlined below:
| Organon generated a negative expected return over the last 90 days | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 |
Organon Quarterly Good Will |
|
Organon uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Organon Co. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Organon's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Organon's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Organon is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Organon Co backward and forwards among themselves. Organon's institutional investor refers to the entity that pools money to purchase Organon's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aqr Capital Management Llc | 2024-06-30 | 3.5 M | Charles Schwab Investment Management Inc | 2024-09-30 | 3.3 M | Citadel Advisors Llc | 2024-09-30 | 2.9 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.7 M | Slate Path Capital Lp | 2024-09-30 | 2.5 M | Thompson, Siegel & Walmsley Llc | 2024-09-30 | 2.3 M | Amvescap Plc. | 2024-06-30 | 2.2 M | Acadian Asset Management Llc | 2024-06-30 | 2.2 M | Private Management Group Inc | 2024-09-30 | 1.9 M | Blackrock Inc | 2024-06-30 | 32.6 M | Vanguard Group Inc | 2024-09-30 | 30.2 M |
Follow Organon's market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 4.12 B.Market Cap |
|
Project Organon's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.15 | 0.14 | |
| Return On Capital Employed | 0.15 | 0.29 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | (14.61) | (13.88) |
When accessing Organon's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Organon's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Organon's profitability and make more informed investment decisions.
Evaluate Organon's management efficiency
Organon has Return on Asset of 0.0791 % which means that on every $100 spent on assets, it made $0.0791 of profit. This is way below average. Organon's management efficiency ratios could be used to measure how well Organon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Capital Employed is likely to grow to 0.29, while Return On Tangible Assets are likely to drop 0.14. At this time, Organon's Other Current Assets are very stable compared to the past year. As of the 28th of November 2024, Non Current Assets Total is likely to grow to about 7.7 B, while Total Assets are likely to drop about 11.9 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.27) | (0.26) | |
| Tangible Book Value Per Share | (20.40) | (21.42) | |
| Enterprise Value Over EBITDA | 8.18 | 4.35 | |
| Price Book Value Ratio | (52.58) | (49.95) | |
| Enterprise Value Multiple | 8.18 | 4.35 | |
| Price Fair Value | (52.58) | (49.95) | |
| Enterprise Value | 14.5 B | 8.7 B |
At Organon, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 1.8882 | Revenue 6.4 B | Quarterly Revenue Growth 0.041 | Revenue Per Share 24.984 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Organon insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Organon Corporate Filings
F4 | 8th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 5th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 1st of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 17th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Organon Earnings per Share Projection vs Actual
Organon Corporate Management
| Susan ONeal | Chief Officer | Profile | |
| Rebecca Edwards | Chief Officer | Profile | |
| Rachel Stahler | Executive Officer | Profile | |
| Susanne Fiedler | Executive Officer | Profile | |
| Daniel Karp | Executive Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.